Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan

Journal of Medical Microbiology

Volumn 61, Issue PART12, 2012, Pages 1727-1735

  Nakano, Ryuichi ^a,b   Nakano, Akiyo ^c   Abe, Michiko ^a   Inoue, Matsuhisa ^a,d   Okamoto, Ryoichi ^a,d  

^a KITASATO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AZABU UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; BETA LACTAMASE CTX M; CEFMETAZOLE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; EPIDEMIC; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PULSED FIELD GEL ELECTROPHORESIS; URINARY TRACT INFECTION; WILD TYPE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFOTAXIME; CROSS INFECTION; DISEASE OUTBREAKS; DNA, BACTERIAL; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; PLASMIDS; PROTEUS INFECTIONS; PROTEUS MIRABILIS;

EID: 84869402543     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.049726-0     Document Type: Article

References (46)

1. Baraniak, A., Fiett, J., Sulikowska, A., Hryniewicz, W. & Gniadkowski, M. (2002). Countrywide spread of CTX-M-3 extended-spectrum blactamase-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 46, 151-159.
2. Batchelor, M., Hopkins, K., Threlfall, E. J., Clifton-Hadley, F. A., Stallwood, A. D., Davies, R. H. & Liebana, E. (2005). blaCTX-M genes in clinical Salmonella isolates recovered from humans in England and Wales from 1992 to 2003. Antimicrob Agents Chemother 49, 1319-1322.
3. Biendo, M., Thomas, D., Laurans, G., Hamdad-Daoudi, F., Canarelli, B., Rousseau, F., Castelain, S. & Eb, F. (2005). Molecular diversity of Proteus mirabilis isolates producing extended-spectrum b-lactamases in a French university hospital. Clin Microbiol Infect 11, 395-401.
4. Birnboim, H. C. & Doly, J. (1979). A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 7, 1513-1523.
5. Bonnet, R., De Champs, C., Sirot, D., Chanal, C., Labia, R. & Sirot, J. (1999). Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother 43, 2671-2677.
6. Bradford, P. A. (2001). Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14, 933-951.
7. Burland, T. G. (2000). DNASTAR's Lasergene sequence analysis software. Methods Mol Biol 132, 71-91.
8. Cantó n, R. & Coque, T. M. (2006). The CTX-M b-lactamase pandemic. Curr Opin Microbiol 9, 466-475.
9. Carattoli, A., Bertini, A., Villa, L., Falbo, V., Hopkins, K. L. & Threlfall, E. J. (2005). Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 63, 219-228.
10. Chanal, C., Bonnet, R., De Champs, C., Sirot, D., Labia, R. & Sirot, J. (2000). Prevalence of b-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother 44, 1930-1935.
11. CLSI (2005). Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute.
12. de Champs, C., Bonnet, R., Sirot, D., Chanal, C. & Sirot, J. (2000). Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother 45, 537-539.
13. Eckert, C., Gautier, V. & Arlet, G. (2006). DNA sequence analysis of the genetic environment of various blaCTX-M genes. J Antimicrob Chemother 57, 14-23.
14. Ford, P. J. & Avison, M. B. (2004). Evolutionary mapping of the SHV b-lactamase and evidence for two separate IS26-dependent blaSHV mobilization events from the Klebsiella pneumoniae chromosome. J Antimicrob Chemother 54, 69-75.
15. Ho, P. L., Ho, A. Y., Chow, K. H., Wong, R. C., Duan, R. S., Ho, W. L., Mak, G. C., Tsang, K. W., Yam, W. C. & Yuen, K. Y. (2005). Occurrence and molecular analysis of extended-spectrum b-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. J Antimicrob Chemother 55, 840-845.
16. Hosaka, Y., Irinoda, K., Nakano, R., Tanabe, S., Koizumi, W., Saigenji, K. & Inoue, M. (2005). Use of the restriction enzyme EcoRI for pulsed-field gel electrophoretic analysis of Helicobacter pylori. J Clin Microbiol 43, 931-932.
17. Jones, B. V., Mahenthiralingam, E., Sabbuba, N. A. & Stickler, D. J. (2005). Role of swarming in the formation of crystalline Proteus mirabilis biofilms on urinary catheters. J Med Microbiol 54, 807-813.
18. Karapavlidou, P., Sofianou, D., Manolis, E. N., Pournaras, S. & Tsakris, A. (2005). CTX-M-1 extended-spectrum b-lactamase-producing Proteus mirabilis in Greece. Microb Drug Resist 11, 351-354.
19. Kim, J. Y., Park, Y. J., Kim, S. I., Kang, M. W., Lee, S. O. & Lee, K. Y. (2004). Nosocomial outbreak by Proteus mirabilis producing extended-spectrum b-lactamase VEB-1 in a Korean university hospital. J Antimicrob Chemother 54, 1144-1147.
20. Lavollay, M., Mamlouk, K., Frank, T., Akpabie, A., Burghoffer, B., Ben Redjeb, S., Bercion, R., Gautier, V. & Arlet, G. (2006). Clonal dissemination of a CTX-M-15 b-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother 50, 2433-2438.
21. Livermore, D. M. & Hawkey, P. M. (2005). CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56, 451-454.
22. Luzzaro, F., Perilli, M., Amicosante, G., Lombardi, G., Belloni, R., Zollo, A., Bianchi, C. & Toniolo, A. (2001). Properties of multidrugresistant, ESBL-producing Proteus mirabilis isolates and possible role of b-lactam/b-lactamase inhibitor combinations. Int J Antimicrob Agents 17, 131-135.
23. Nagano, N., Shibata, N., Saitou, Y., Nagano, Y. & Arakawa, Y. (2003). Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type b-lactamase. J Clin Microbiol 41, 5530-5536.
24. Nakano, R., Okamoto, R., Nakano, Y., Kaneko, K., Okitsu, N., Hosaka, Y. & Inoue, M. (2004). CFE-1, a novel plasmid-encoded AmpC b-lactamase with an ampR gene originating from Citrobacter freundii. Antimicrob Agents Chemother 48, 1151-1158.
25. Nakano, R., Okamoto, R., Nagano, N. & Inoue, M. (2007). Resistance to gram-negative organisms due to high-level expression of plasmidencoded ampC b-lactamase blaCMY-4 promoted by insertion sequence ISEcp1. J Infect Chemother 13, 18-23.
26. Novais, A., Cantó n, R., Valverde, A., Machado, E., Galá n, J. C., Peixe, L., Carattoli, A., Baquero, F. & Coque, T. M. (2006). Dissemination and persistence of blaCTX-M-9 are linked to class 1 integrons containing CR1 associated with defective transposon derivatives from Tn402 located in early antibiotic resistance plasmids of IncHI2, IncP1-a, and IncFI groups. Antimicrob Agents Chemother 50, 2741-2750.
27. Odakura, Y., Hashimoto, H. & Mitsuhashi, S. (1977). Temperature sensitive R plasmids isolated from Proteus strains. Microbiol Immunol 21, 621-629.
28. Park, Y. J., Lee, S., Kim, Y. R., Oh, E. J., Woo, G. J. & Lee, K. (2006). Occurrence of extended-spectrum b-lactamases and plasmidmediated AmpC b-lactamases among Korean isolates of Proteus mirabilis. J Antimicrob Chemother 57, 156-158.
29. Paterson, D. L. & Bonomo, R. A. (2005). Extended-spectrum blactamases: a clinical update. Clin Microbiol Rev 18, 657-686.
30. Pé rez-Pé rez, F. J. & Hanson, N. D. (2002). Detection of plasmidmediated AmpC b-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40, 2153-2162.
31. Poirel, L., Decousser, J. W. & Nordmann, P. (2003). Insertion sequence ISEcp1B is involved in expression and mobilization of a blaCTX-M blactamase gene. Antimicrob Agents Chemother 47, 2938-2945.
32. Quinteros, M., Radice, M., Gardella, N., Rodriguez, M. M., Costa, N., Korbenfeld, D., Couto, E., Gutkind, G. & Microbiology Study Group (2003). Extended-spectrum b-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 47, 2864-2867.
33. Radice, M., Power, P., Di Conza, J., Gutkind, G., Bonnet, R., Sirot, D., Sirot, J. & Labia, R. (2002). Early dissemination of CTX-M-derived enzymes in South America. Antimicrob Agents Chemother 46, 602-604.
34. Rossolini, G. M., D'Andrea, M. M. & Mugnaioli, C. (2008). The spread of CTX-M-type extended-spectrum b-lactamases. Clin Microbiol Infect 14 (Suppl. 1), 33-41.
35. Ró zalski, A., Sidorczyk, Z. & Kotełko, K. (1997). Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 61, 65-89.
36. Saladin, M., Cao, V. T., Lambert, T., Donay, J. L., Herrmann, J. L., Ould-Hocine, Z., Verdet, C., Delisle, F., Philippon, A. & Arlet, G. (2002). Diversity of CTX-M b-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 209, 161-168.
37. Sanger, F., Nicklen, S. & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74, 5463-5467.
38. Saurina, G., Quale, J. M., Manikal, V. M., Oydna, E. & Landman, D. (2000). Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 45, 895-898.
39. Shapiro, J. (1977). Appendix B: Bacterial Plasmids. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
40. Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H. & Swaminathan, B. (1995). Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33, 2233-2239.
41. Verdet, C., Arlet, G., Ben Redjeb, S., Ben Hassen, A., Lagrange, P. H. & Philippon, A. (1998). Characterisation of CMY-4, an AmpC-type plasmid-mediated b-lactamase in a Tunisian clinical isolate of Proteus mirabilis. FEMS Microbiol Lett 169, 235-240.
42. Villegas, M. V., Correa, A., Perez, F., Miranda, M. C., Zuluaga, T., Quinn, J. P. & Colombian Nosocomial Resistance Study Group (See) (2004). Prevalence and characterization of extended-spectrum b-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn Microbiol Infect Dis 49, 217-222.
43. Woodford, N., Ward, M. E., Kaufmann, M. E., Turton, J., Fagan, E. J., James, D., Johnson, A. P., Pike, R., Warner, M. & other authors (2004). Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum b-lactamases in the UK. J Antimicrob Chemother 54, 735-743.
44. Wu, L. T., Wu, H. J., Chung, J. G., Chuang, Y. C., Cheng, K. C. & Yu, W. L. (2006). Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 b-lactamases at 2 hospitals in Taiwan. Diagn Microbiol Infect Dis 54, 89-94.
45. Yagi, T., Kurokawa, H., Shibata, N., Shibayama, K. & Arakawa, Y. (2000). A preliminary survey of extended-spectrum b-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 184, 53-56.
46. Yano, H., Kuga, A., Okamoto, R., Kitasato, H., Kobayashi, T. & Inoue, M. (2001). Plasmid-encoded metallo-b-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 45, 1343-1348.